HRCT定量评价吸入糖皮质激素治疗哮喘患儿的效果

doi:10.7517/issn.1674-0475.210822

摘要/Abstract

摘要： 本次研究目的是探讨高分辨CT(HRCT)定量评价吸入糖皮质激素治疗哮喘患儿的临床效果。选取哮喘患儿118例,将患儿分为观察组(n=63)和对照组(n=55),对照组给予常规治疗,观察组在对照组基础上给予丙酸氟替卡松雾剂或布地奈德气雾剂,观察两组治疗疗效,采用HRCT测量肺CT的段及亚段支气管壁厚度/气道外径(T/D)和气道壁面积占气道总面积百分比(WA)。观察组治疗疗效优于对照组(P<0.05);观察组治疗后T/D、WA明显低于对照组(P<0.05);与无效患者比较,有效患者治疗后T/D、WA较低(P<0.05);在预测预测治疗有效方面,T/D、WA变化值的ROC曲线下面积分别为0.859和0.826,P<0.05。吸入性糖皮质激素治疗哮喘患儿有较好的疗效,HRCT定量参数预测治疗疗效方面有一定价值。

关键词: 吸入性, 糖皮质激素, 哮喘, 儿童, 临床疗效

Abstract: The purpose of this study was to evaluate the clinical effect of inhaled glucocorticoids on asthmatic children by high resolution CT (HRCT). 118 children with asthma were divided into observation group (n=63) and control group (n=55). The control group was given routine treatment, the observation group was given fluticasone propionate aerosol or Budesonide aerosol on the basis of the control group, the therapeutic effects of the two groups were observed, the thickness of segmental and sub segmental bronchial wall/airway outer diameter (T/D) and the percentage of airway wall area in total airway area (WA) were measured by HRCT. The therapeutic effect of the observation group was better than that of the control group (P<0.05). T/D and WA in the observation group were significantly lower than those in the control group (P<0.05). Compared with ineffective patients, effective patients had lower T/D and WA after treatment (P<0.05). The area under ROC curve of T/D and WA was 0.859 and 0.826, respectively, P<0.05. Inhaled glucocorticoids have a good effect on children with asthma, and HRCT quantitative parameters have a certain value in predicting the therapeutic effect.

Key words: inhaled, glucocorticoid, asthma, children, clinical efficacy

莫畅游, 李超, 谢云. HRCT定量评价吸入糖皮质激素治疗哮喘患儿的效果[J]. 影像科学与光化学, 2022, 40(2): 320-324.

MO Changyou, LI Chao, XIE Yun. HRCT Quantitative Evaluation of the Clinical Effect of Inhaled Corticosteroids in the Treatment of Children with Asthma[J]. IMAGING SCIENCE AND PHOTOCHEMISTRY, 2022, 40(2): 320-324.

参考文献

[1] 尉耘翠, 贾露露, 张萌, 等. 儿科医师对哮喘控制类用药——吸入性糖皮质激素的用药选择及对患者用药依从性评价的调查[J]. 中国药房, 2019, 30(3):408-412.
[2] 张敏, 温志红, 杨彩琼. 达良好控制哮喘患儿停用低剂量吸入性糖皮质激素的临床随访研究[J]. 中国当代儿科杂志, 2019, 21(5):421-425.
[3] 尉耘翠, 贾露露, 胡利华, 等. 儿童哮喘缓解期吸入性糖皮质激素用药依从性现况调查[J]. 中国医院药学杂志, 2019, 39(14):1494-1498.
[4] 黄传君, 赵方正, 陈方方, 等. 吸入性糖皮质激素能有效控制支气管哮喘气道炎症[J]. 中华结核和呼吸杂志, 2018, 41(11):912.
[5] 薛满, 喻钧. 不同联合药物雾化吸入方案对儿童支气管哮喘急性发作治疗效果及安全性的影响[J]. 中国妇幼保健, 2019, 34(3):550-553.
[6] 中华医学会儿科学分会呼吸学组, 《中华儿科杂志》编辑委员会. 儿童支气管哮喘诊断与防治指南(2016年版)[J]. 中华儿科杂志, 2016, 54(3):167-181.
[7] Maselli D J, Peters J I. Quadrupling inhaled glucocorticoid dose for deteriorating asthma control reduced severe exacerbations[J]. Annals of Internal Medicine, 2018, 168(12):65-66.
[8] McKeever T, Mortimer K, Wilson A, et al. Quadrupling inhaled glucocorticoid dose to abort asthma exacerbations[J]. The New England Journal of Medicine, 2018, 378(10):902-910.
[9] Hashim Z, Neyaz Z, Kumar S, et al. Correlation of asthma severity, IgE level, and spirometry results with HRCT findings in allergic bronchopulmonary aspergillosis[J]. Indian Journal of Radiology and Imaging, 2020, 30(2):163-164.
[10] Tanabe N, Sato S, Oguma T, et al. Influence of asthma onset on airway dimensions on ultra-high-resolution computed tomography in chronic obstructive pulmonary disease[J]. Journal of Thoracic Imaging, 2021, 36(4):224-230.
[11] Silva T K B D, Zanon M, Altmayer S, et al. High-resolution CT pulmonary findings in children with severe asthma[J]. Jornal De Pediatria, 2021, 97(1):37-43.
[12] Lin X F, Lin Y J, Lai Z D, et al. Retrospective comparison of high-resolution computed tomography of eosinophilic granulomatosis with polyangiitis with severe asthma[J]. Annals of Translational Medicine, 2021, 9(12):983-984.
[13] Jung J W, Oh J S, Bae B, et al. Ultra-high-resolution computed tomography shows changes in the lungs related with airway hyperresponsiveness in a murine asthma model[J]. Scientific Reports, 2021, 11(1):17584-17585.
[14] 徐盛威. HRCT在儿童支气管哮喘诊断中的应用[J]. 影像研究与医学应用, 2021, 5(5):218-219.
[15] Hashimoto M, Tanaka H, Abe S. Quantitative analysis of bronchial wall vascularity in the medium and small airways of patients with asthma and COPD[J]. Chest, 2005, 127(3):965-972.
[16] Choi J Y, Yoon H K, Lee J H, et al. Nationwide use of inhaled corticosteroids by South Korean asthma patients:An examination of the Health Insurance Review and Service database[J]. Journal of Thoracic Disease, 2018, 10(9):5405-5413.
[17] Awadh N, Müller N L, Park C S, et al. Airway wall thickness in patients with near fatal asthma and control groups:Assessment with high resolution computed tomographic scanning[J]. Thorax, 1998, 53(4):248-253.
[18] Yang M J, Zhang Y, Chen H, et al. Inhaled corticosteroids and risk of upper respiratory tract infection in patients with asthma:A meta-analysis[J]. Infection, 2019, 47(3):377-385.
[19] Choi Y J, Lee H Y, Yoon D, et al. Trabecular bone score is more sensitive to asthma severity and glucocorticoid treatment than bone mineral density in asthmatics[J]. Allergy, Asthma & Immunology Research, 2019, 11(3):343-356.